Feb. 8, 2024

The Centers for Medicare and Medicaid Services (CMS) Measures Management System posted a public comment period, open through Feb. 26, for four new breast cancer-related measures developed by Acumen, LLC. These include three quality measures and one episode-based cost measure intended to assess clinician performance in breast cancer screening and diagnosis and improve patient outcomes. An informational webinar about the measures will be held Feb. 13, 3–4pm ET.

The codes are:

  • Breast Cancer Screening Recall Rate Quality Measure (Outcome).
  • Breast Cancer Screening with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 1 (PPV1) Quality Measure (Outcome).
  • Use of Biopsy After Diagnostic Follow-up with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 3 (PPV3) Quality Measure (Outcome).
  • Breast Cancer Screening Episode-Based Cost Measure.

The testing process is an important step in determining whether these measures could eventually be adopted into CMS’ Merit-based Incentive Payment System. Feedback can be provided via the 2024 Beta Testing Feedback Survey through 11:59pm ET, Feb. 26.

If you have questions, contact Samantha Shugarman, American College of Radiology® Director of Quality Programs.


Related ACR News

  • State Legislative Bills Report

    As most state legislatures end their 2025 sessions and look to 2026, ACR staff is looking at how some radiology-specific bills they tracked fared this year.

    Read more
  • Medicare Payment Increase in Final Budget Reconciliation Bill

    The bill includes a 2.5% increase to the Medicare Physician Fee Schedule for calendar year 2026.

    Read more
  • CMS Announces Prior Authorization Test Model

    WiSer is a six-year program that will begin in six states on January 1, 2026. It will introduce prior authorization using AI technology for a select number of services, including some IR procedures.

    Read more